AdipoGen Life Sciences COVID-19 antiviral research compounds
There are no approved drugs to treat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19). Existing drugs, which have a known favourable safety profile, are being examined for strategies to treat the disease and fast-track a treatment plan. Several influenza and HIV drugs are currently undergoing clinical trial in coronavirus patients. The rational selection of drugs already on the market is being made based on their ability to inhibit any proteins essential for virus-receptor interaction and/or viral life cycle.
AdipoGen Life Sciences’ range of Small Molecule SARS-CoV-2 Inhibitors and Modulators offers potential tools for in vitro studies of COVID-19. The company’s product range includes research compounds targeting viral transcription, replication and maturation.
Phone: 02 9698 2022
Microbiologics UV-BioTAG QC microorganisms for quality control testing
UV-BioTAG, a line of reference strains containing green fluorescent protein (GFP) markers, makes...
ProSci Incorporated ferroptosis antibodies
ProSci Incorporated's range of ferroptosis antibodies includes AIFM2, NCOA4, PEX3, PEX10,...
BioClean-D Coverall with Hood and Integrated Boots – Sterile S-BDFC
Sterile coveralls act as a barrier, preventing particles, dust, microbes and other contaminants...